Haemarthrosis stimulates the synovial fibrinolytic system in haemophilic mice

Thrombosis and Haemostasis

Volumn 110, Issue 1, 2013, Pages 173-183

  Nieuwenhuizen, Laurens ^a,b   Roosendaal, Goris ^b   Coeleveld, Katja ^a   Lubberts, Erik ^c   Biesma, Douwe H ^b   Lafeber, Floris P J G ^a   Schutgens, Roger E G ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Fibrinolysis; Haemarthrosis; Haemophilia; Haemophilic arthropathy; Synovium

Indexed keywords

ALPHA 2 ANTIPLASMIN; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARTILAGE; CONTROLLED STUDY; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; HEMARTHROSIS; HEMOPHILIA; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNOVIOCYTE; SYNOVIUM;

ALPHA-2-ANTIPLASMIN; ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FIBRINOLYSIN; FIBRINOLYSIS; FIBROBLASTS; HEMARTHROSIS; HEMOPHILIA A; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLASMINOGEN ACTIVATOR INHIBITOR 1; SYNOVIAL MEMBRANE; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84879638968     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-01-0080     Document Type: Article

References (48)

1. Lafeber FP, Miossec P, Valentino LA. Physiopathology of haemophilic arthropathy. Haemophilia 2008; 14 (Suppl 4): 3-9.
2. Mulder K, Llinas A. The target joint Haemophilia 2004; 10 (Suppl 4): 152-156.
3. Acharya SS, Kaplan RN, Macdonald D, et al. Neoangiogenesis contributes to the development of haemophilic synovitis. Blood 2011; 117: 2484-2493.
4. Madhok R, Bennett D, Sturrock RD, et al. Mechanisms of joint damage in an experimental model of haemophilic arthritis. Arthritis Rheum 1988; 31: 1148-1155.
5. Jansen NW, Roosendaal G, Bijlsma JW, et al. Exposure of human cartilage tissue to low concentrations of blood for a short period of time leads to prolonged cartilage damage: an in vitro study. Arthritis Rheum 2007; 56: 199-207.
6. Roosendaal G, Vianen ME, Marx JJ, et al. Blood-induced joint damage: a human in vitro study. Arthritis Rheum 1999; 42: 1025-1032.
7. Storti E, Magrini U, Ascari E. Synovial fibrinolysis and haemophilic haemarthrosis. Br Med J 1971; 4: 812.
8. Pandolfi M, Ahlberg A, Traldi A, et al. Fibrinolytic activity of human synovial membranes in health and in haemophilia. Scand J Haematol 1972; 9: 572-576.
9. Busso N, Peclat V, So A, et al. Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints. Ann Rheum Dis 1997; 56: 550-557.
10. Kummer JA, Abbink JJ, de Boer JP, et al. Analysis of intraarticular fibrinolytic pathways in patients with inflammatory and noninflammatory joint diseases. Arthritis Rheum 1992; 35: 884-893.
11. Mayer P. Notiz über Hämateïn und Hämalaun. Zeitschrift Wissensch Mikroskopie Mikrosk Technik 1903; 20: 409-409.
12. Hakobyan N, Enockson C, Cole AA, et al. Experimental haemophilic arthropathy in a mouse model of a massive haemarthrosis: gross, radiological and histological changes. Haemophilia 2008; 14: 804-809.
13. Holmberg H, Kiersgaard MK, Mikkelsen LF, et al. Impact of blood sampling technique on blood quality and animal welfare in haemophilic mice. Lab Anim 2011; 45: 114-120.
14. Valentino LA, Hakobyan N, Kazarian T, et al. Experimental haemophilic synovitis: rationale and development of a murine model of human factor VIII deficiency. Haemophilia 2004; 10: 280-287.
15. Lubberts E, Joosten LA, Oppers B, et al. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 2001; 167: 1004-1013.
16. Rosengren S, Boyle DL, Firestein GS. Acquisition, culture, and phenotyping of synovial fibroblasts. Methods Mol Med 2007; 135: 365-375.
17. Whiteman P. The quantitative measurement of Alcian Blue-glycosaminoglycan complexes. Biochem J 1973; 131: 343-350.
18. Rodriguez-Merchan EC. Pathogenesis, early diagnosis, and prophylaxis for chronic haemophilic synovitis. Clin Orthop Relat Res 1997; 6-11.
19. Broze GJ, Jr., Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from haemophilic plasma. Blood 1996; 88: 3815-3823.
20. Foley JH, Nesheim ME. Soluble thrombomodulin partially corrects the premature lysis defect in FVIII-deficient plasma by stimulating the activation of thrombin activatable fibrinolysis inhibitor. J Thromb Haemost 2009; 7: 453-459.
21. Mosnier LO, Lisman T, van den Berg HM, et al. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost 2001; 86: 1035-1039.
22. Grigorjeva M, Golubeva M, Jakunina L, et al. The State of Fibrinolytic and Coagulation Systems in Haemophiliacs. J Thromb Haemost 2005; 3 (Suppl): 819.
23. Grunewald M, Siegemund A, Grunewald A, et al. Paradoxical hyperfibrinolysis is associated with a more intensely haemorrhagic phenotype in severe congenital haemophilia. Haemophilia 2002; 8: 768-775.
24. Crippa MP. Urokinase-type plasminogen activator. Int J Biochem Cell Biol 2007; 39: 690-694.
25. Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009; 7: 4-13.
26. Ronday HK, Smits HH, Van Muijen GN, et al. Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Br J Rheumatol 1996; 35: 416-423.
27. Yoshida E, Ohmura S, Sugiki M, et al. A novel function of extraerythrocytic haemoglobin: identification of globin as a stimulant of plasminogen activator biosynthesis in human fibroblasts. Thromb Haemost 2001; 86: 1521-1527.
28. Kruithof EK. Plasminogen activator inhibitors--a review. Enzyme 1988; 40: 113-121.
29. Declerck PJ, De Mol M, Vaughan DE, Collen D. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator. J Biol Chem 1992; 267: 11693-11696.
30. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005; 129: 307-321.
31. Pandey M, Loskutoff DJ, Samad F. Molecular mechanisms of tumor necrosis factor-alpha-mediated plasminogen activator inhibitor-1 expression in adipocytes. FASEB J 2005; 19: 1317-1319.
32. Goulding NJ, Dixey J, Morand EF, et al. Differential distribution of annexins-I, -II, -IV, and -VI in synovium. Ann Rheum Dis 1995; 54: 841-845.
33. Coughlin PB. Antiplasmin: the forgotten serpin? FEBS J 2005; 272: 4852-4857.
34. Collen D, Wiman B. Turnover of antiplasmin, the fast-acting plasmin inhibitor of plasma. Blood 1979; 53: 313-324.
35. Dargaud Y, Simpson H, Chevalier Y, et al. The potential role of synovial thrombomodulin in the pathophysiology of joint bleeds in haemophilia. Haemophilia 2012; 18: 818-823.
36. Brinkmann T, Kahnert H, Prohaska W, et al. Synthesis of tissue factor pathway inhibitor in human synovial cells and chondrocytes makes joints the predilected site of bleeding in haemophiliacs. Eur J Clin Chem Clin Biochem 1994; 32: 313-317.
37. So AK, Varisco PA, Kemkes-Matthes B, et al. Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost 2003; 1: 2510-2515.
38. Belcher C, Fawthrop F, Bunning R, et al. Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees. Ann Rheum Dis 1996; 55: 230-236.
39. Alturfan AA, Eralp L, Emekli N. Investigation of inflammatory and haemostatic parameters in female patients undergoing total knee arthroplasty surgery. Inflammation 2008; 31: 414-421.
40. Jin T, Tarkowski A, Carmeliet P, et al. Urokinase, a constitutive component of the inflamed synovial fluid, induces arthritis. Arthritis Res Ther 2003; 5: R9-R17.
41. Li J, Ny A, Leonardsson G, et al. The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis. Am J Pathol 2005; 166: 783-792.
42. Furmaniak-Kazmierczak E, Cooke TD, Manuel R, et al. Studies of thrombin-induced proteoglycan release in the degradation of human and bovine cartilage. J Clin Invest 1994; 94: 472-480.
43. Carmeliet P, Moons L, Lijnen R, et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997; 17: 439-444.
44. Monea S, Lehti K, Keski-Oja J, et al. Plasmin activates pro-matrix metalloproteinase- 2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J Cell Physiol 2002; 192: 160-170.
45. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, et al. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 1999; 274: 13066-13076.
46. Hvas AM, Sorensen HT, Norengaard L, et al. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe haemophilia A. J Thromb Haemost 2007; 5: 2408-2414.
47. Rainsford SG, Jouhar AJ, Hall A. Tranexamic acid in the control of spontaneous bleeding in severe haemophilia. Thromb Diath Haemorrh 1973; 30: 272-279.
48. Astermark J, Rocino A, Von Depka M, et al. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors. Haemophilia 2007; 13: 38-45.